Literature DB >> 7438552

Mechanisms of protective immunogenicity of microbial vaccines: effects of cyclophosphamide pretreatment in Venezuelan encephalitis, Q fever and tularaemia.

M S Ascher, P B Jahrling, D G Harrington, R A Kishimoto, V G McGann.   

Abstract

Administration of high-dose (250 mg/kg) cyclophosphamide (CY) to guinea-pigs and mice 3 days prior to immunization with inactivated vaccine derived from Venezuelan encephalitis virus (VE), Coxiella burnetii and Francisella tularensis resulted in accentuated and prolonged delayed-type hypersensitivity (DTH) and in vitro cellular immunity (CMI) to specific antigen. Humoral antibody were either absent or significantly lower in CY-pretreated animals compared to immunized non-pretreated controls. CY pretreatments precluded protection in the VE virus model, suggesting that resistance is related to antibody. In the Q fever model, the protective immunogenicity of vaccine was preserved or increased by CY pretreatment suggesting that cell-mediated immunity is the important factor. In the tularaemia bacterial system, there was a complex effect of CY pretreatment on the low-grade protection afforded by killed vaccine against virulent infection. These findings suggest that the inability of killed vaccines to induce high-grade resistance against tularaemia and Q fever may be due in part to a suppressive B cell response which is eliminated by CY. These studies have given useful information on the relative significance of components of the specific immune response and may lead to an increased understanding of the mechanisms of action of vaccines and adjuvants.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438552      PMCID: PMC1536999     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  56 in total

1.  CELLULAR IMMUNITY OF RATS TO TULAREMIA.

Authors:  J M WOODWARD; M H STANSBERRY; W G PRESSWOOD; J B FOX
Journal:  Can J Microbiol       Date:  1964-08       Impact factor: 2.419

2.  The development of resistance in mice immunized with soluble antigen derived from Bacterium tularense.

Authors:  C L LARSON; J F BELL; C R OWEN
Journal:  J Immunol       Date:  1954-10       Impact factor: 5.422

3.  Effects of variation in time and dose of cyclophosphamide injection on delayed hypersensitivity and antibody formation.

Authors:  J A Kerckhaert; F M Hofhuis; J M Willers
Journal:  Cell Immunol       Date:  1977-03-15       Impact factor: 4.868

4.  Modification of cutaneous leishmaniasis in the guinea-pig by cyclophosphamide.

Authors:  A Belehu; L W Poulter; J L Turk
Journal:  Clin Exp Immunol       Date:  1976-04       Impact factor: 4.330

5.  The role of antibody in recovery from experimental rabies. I. Effect of depletion of B and T cells.

Authors:  A Miller; H C Morse; J Winkelstein; N Nathanson
Journal:  J Immunol       Date:  1978-07       Impact factor: 5.422

6.  Cell-mediated immune responses of guinea pigs to an inactivated phase I Coxiella burnetii vaccine.

Authors:  R A Kishimoto; J W Johnson; R H Kenyon; M S Ascher; E W Larson; C E Pedersen
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

7.  Effect of cyclophosphamide on the immune response to Pseudomonas aeruginosa in mice.

Authors:  C L Pierson; A G Johnson; I Feller
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

8.  Cyclophosphamide pretreatment and protection against malaria.

Authors:  J F Finerty; E P Krehl
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

9.  Cyclophosphamide effects on murine cryptococcosis.

Authors:  J R Graybill; L Mitchell
Journal:  Infect Immun       Date:  1978-08       Impact factor: 3.441

10.  Immunity against tularemia: passive protection of mice by transfer of immune tissues.

Authors:  W P ALLEN
Journal:  J Exp Med       Date:  1962-02-01       Impact factor: 14.307

View more
  5 in total

1.  Both inducible nitric oxide synthase and NADPH oxidase contribute to the control of virulent phase I Coxiella burnetii infections.

Authors:  Robert E Brennan; Kasi Russell; Guoquan Zhang; James E Samuel
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

2.  Experimental model for dermal granulomatous hypersensitivity in Q fever.

Authors:  M S Ascher; M A Berman; D Parker; J L Turk
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

3.  Dermal granulomatous hypersensitivity in Q fever: comparative studies of the granulomatous potential of whole cells of Coxiella burnetii phase I and subfractions.

Authors:  M S Ascher; J C Williams; M A Berman
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

4.  Antibody-dependent cellular cytotoxicity of Coxiella burnetii-infected J774 macrophage target cells.

Authors:  F T Koster; T L Kirkpatrick; J D Rowatt; O G Baca
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

Review 5.  Preclinical Animal Models for Q Fever Vaccine Development.

Authors:  Mahelat Tesfamariam; Picabo Binette; Carrie Mae Long
Journal:  Front Cell Infect Microbiol       Date:  2022-02-10       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.